{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

AINewsBreaks – Massimo Group (NASDAQ: MAMO) Launches Fleet and Commercial Vehicle Program, Expands Beyond Retail Channels

December 18, 2025 — Massimo Group (NASDAQ: MAMO) announced the launch of a dedicated Fleet and Commercial Vehicle Program, marking a strategic expansion beyond traditional retail sales and targeting fleet-oriented customers such as security operations, municipalities, campuses, grounds maintenance providers, and commercial facilities. The manufacturer and distributor of powersports and electric vehicles said the program will initially focus on its newly introduced MVR HVAC electric vehicle series, which features fully enclosed cabs with heating and air conditioning designed for high-utilization, year-round operation, with a structured go-to-market strategy that includes direct fleet engagement, trade show participation, and dedicated commercial sales efforts to support repeat purchasing and long-term customer relationships.

AINewsBreaks – BluSky Ai Inc. (OTCID: BSAI) Featured in Research Report Highlighting Scalable GPU-Centric AI Platform

December 18, 2025 — BluSky Ai (OTCID: BSAI), a developer of artificial intelligence infrastructure software, was the subject of a December 2025 independent research report published by Globe Small Cap Research LLC that reviewed the company’s distributed GPU-centric AI platform and its potential role in addressing growing demand for scalable compute resources. The report examines BluSky Ai’s centralized cloud software architecture designed to aggregate geographically dispersed GPU modules into a single elastic pool, enabling enterprises and public-sector users to deploy AI workloads without relying solely on traditional centralized data centers.

Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) Strengthens Indigenous, Community Partnerships to Support Responsible REE Development

December 18, 2025 — A central pillar of Search Mineral’s commitment to the community is its long-standing partnership with the NunatuKavut Community Council The company further reinforces this partnership through its governance structure Search Minerals also maintains frequent dialogue with leaders in St. Lewis, Mary’s Harbour and Port Hope Simpson Disseminated on behalf of Search Minerals Inc.

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1

December 18, 2025 — Telomir Pharmaceuticals (NASDAQ: TELO) announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1 (Zn-Telomir), reporting no treatment-related adverse or dose-limiting toxicities across cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models. The preclinical-stage biotechnology company said Telomir-1 was well tolerated with no concerning cardiac or respiratory safety signals, no phototoxic potential, and only limited, reversible, and non-adverse findings in repeated-dose studies, while demonstrating consistent systemic exposure and predictable pharmacokinetics following oral administration, supporting continued advancement toward first-in-human clinical development pending completion of final quality assurance review and applicable regulatory pathways.

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease

December 18, 2025 — Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in oral ulcers and pain and favorable area under the curve measurements, were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration.